STAT3 and triple-negative breast carcinoma: Previous studies have mechanistically shown that flubendazole elicits antitumor effects by inhibiting STAT3 in triple-negative breast carcinoma and colorectal carcinoma (Oh et al., 2018; Lin et al., 2019).